Acceleron Pharma Inc (XLRN) : Qvt Financial Lp reduced its stake in Acceleron Pharma Inc by 9.35% during the most recent quarter end. The investment management company now holds a total of 636,764 shares of Acceleron Pharma Inc which is valued at $25,585,178 after selling 65,646 shares in Acceleron Pharma Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Acceleron Pharma Inc makes up approximately 1.48% of Qvt Financial Lp’s portfolio.
Other Hedge Funds, Including , Price T Rowe Associates Inc Md boosted its stake in XLRN in the latest quarter, The investment management firm added 140,567 additional shares and now holds a total of 3,284,766 shares of Acceleron Pharma Inc which is valued at $131,981,898. Acceleron Pharma Inc makes up approx 0.03% of Price T Rowe Associates Inc Md’s portfolio.Granite Point Capital Management reduced its stake in XLRN by selling 1,500 shares or 10.04% in the most recent quarter. The Hedge Fund company now holds 13,441 shares of XLRN which is valued at $453,768. Acceleron Pharma Inc makes up approx 0.40% of Granite Point Capital Management’s portfolio.Blackrock Japan Ltd boosted its stake in XLRN in the latest quarter, The investment management firm added 127 additional shares and now holds a total of 221 shares of Acceleron Pharma Inc which is valued at $6,080.Nationwide Fund Advisors boosted its stake in XLRN in the latest quarter, The investment management firm added 2,077 additional shares and now holds a total of 25,951 shares of Acceleron Pharma Inc which is valued at $776,973.
Acceleron Pharma Inc closed down -0.19 points or -0.50% at $37.96 with 4,55,457 shares getting traded on Monday. Post opening the session at $37.74, the shares hit an intraday low of $36.44 and an intraday high of $38.16 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Acceleron Pharma Inc reported $-0.55 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.54.Analysts expectations of $ 4.19.
Many Wall Street Analysts have commented on Acceleron Pharma Inc. Citigroup Initiated Acceleron Pharma Inc on Sep 29, 2016 to “Neutral”, Price Target of the shares are set at $40.
Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s research focuses on key natural regulators of cellular growth and repair particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. By combining its discovery and development know-how including its knowledge of the TGF-b superfamily and its internal protein engineering and manufacturing capabilities the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action. The Company has four internally discovered therapeutic candidates that are in clinical trials.